Compare · CHRO vs RVMD
CHRO vs RVMD
Side-by-side comparison of Channel Therapeutics Corporation (CHRO) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CHRO and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD carries a market cap of $31.73B.
- Over the past year, CHRO is up 8.3% and RVMD is up 271.4% - RVMD leads by 263.1 points.
- RVMD has hit the wire 5 times in the past 4 weeks while CHRO has been quiet.
- RVMD has more recent analyst coverage (25 ratings vs 0 for CHRO).
- Company
- Channel Therapeutics Corporation
- Revolution Medicines Inc.
- Price
- $1.31+0.77%
- $150.81+1.08%
- Market cap
- -
- $31.73B
- 1M return
- +8.26%
- +5.70%
- 1Y return
- +8.26%
- +271.41%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- AMEX
- NASDAQ
- IPO
- 2024
- 2020
- News (4w)
- 0
- 5
- Recent ratings
- 0
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest CHRO
- SEC Form D filed by Channel Therapeutics Corporation
- Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum
- SEC Form SCHEDULE 13G filed by Channel Therapeutics Corporation
- SEC Form 4 filed by Director Baxter Richard B
- SEC Form 4 filed by Director Greenleaf Peter
- SEC Form 4 filed by Director Pauls Matthew
- SEC Form 4 filed by CFO, Treas & Secty Francis Knuettel Ii
- SEC Form 4 filed by Director Davis Todd C
- SEC Form 4 filed by Director Friedberg Ezra M
- SEC Form 4 filed by Director Malamut Richard
Latest RVMD
- Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
- Officer Mancini Anthony exercised 3,121 shares at a strike of $33.62 and sold $480,611 worth of shares (3,121 units at $153.99) as part of a pre-agreed trading plan (SEC Form 4)
- Bernstein initiated coverage on Revolution Medicines with a new price target
- Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
- Truist resumed coverage on Revolution Medicines with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
- SEC Form 10-Q filed by Revolution Medicines Inc.
- Revolution Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress